股本结构
单位：万股
| 公告日期 | 2024-04-08 | 2024-04-08 | 2023-11-14 | 2023-06-13 | 2023-05-15 | 2022-12-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 630.74 | 536.21 | 518.11 | 505.25 | 505.25 | 421.07 |
| 普通股本 | 630.74 | 536.21 | 518.11 | 505.25 | 505.25 | 421.07 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-25 | 2023-12-31 | 2023-11-10 | 2023-06-12 | 2023-03-31 | 2022-12-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-08 | 630.74 | 未披露 | 定期报告 | 2024-03-25 |
| 2024-04-08 | 536.21 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Redemptions of convertible debt into common stock
Voluntary conversion of convertible debt into common stock
|
2023-12-31 |
| 2023-11-14 | 518.11 | 未披露 | 定期报告 | 2023-11-10 |
| 2023-06-13 | 505.25 | 未披露 | 定期报告 | 2023-06-12 |
| 2023-05-15 | 505.25 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Voluntary conversion of convertible debt into common stock
|
2023-03-31 |
| 2022-12-30 | 421.07 | 未披露 | 定期报告 | 2022-12-30 |
| 2022-11-22 | 421.10 | 未披露 |
更多>>
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split.
|
2022-11-23 |
| 2022-11-14 | 4211.02 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Stock issued upon exercise of warrants
|
2022-09-30 |
| 2022-06-17 | 3879.55 | 未披露 | 定期报告 | 2022-06-15 |
| 2022-03-31 | 3529.55 | 未披露 | 定期报告 | 2022-03-25 |
| 2022-03-31 | 3529.02 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock for conversion of preferred stock
Stock issued upon cash-exercise of warrants
Stock issued upon net-exercise of warrants
Shares issued pursuant to Securities Purchase Agreements
Stock issued for professional services
|
2021-12-31 |
| 2021-12-01 | 2940.75 | 未披露 | 定期报告 | 2021-11-30 |
| 2021-11-15 | 2911.71 | 未披露 | 定期报告 | 2021-11-11 |
| 2021-11-15 | 2908.21 | 0.02 |
更多>>
From June 30, 2021 to September 30, 2021
Stock issued upon cash-exercise of warrants
|
2021-09-30 |
| 2021-08-16 | 2899.88 | 未披露 | 定期报告 | 2021-08-12 |
| 2021-08-16 | 2890.22 | 0.02 |
更多>>
From March 31, 2021 to June 30, 2021
Stock issued upon cash-exercise of warrants
|
2021-06-30 |
| 2021-05-14 | 2883.31 | 0.02 |
更多>>
From December 31, 2020 To March 31, 2021
Stock issued upon cash-exercise of warrants
Stock issued upon net-exercise of warrants
Stock issued for professional services
|
2021-03-31 |
| 2021-03-31 | 2878.07 | 未披露 | 定期报告 | 2021-03-15 |
| 2021-03-31 | 2729.61 | 0.02 |
更多>>
From March 31, 2020 to December 31, 2020
Issuance of common stock for conversion of preferred stock
Issuance of common stock for conversion of notes payable and accrued interest
Effect of reverse recapitalization
Shares and warrants issued to advisor upon closing of private placement
Shares and warrants issued pursuant to Securities Purchase Agreements
Stock issued for professional services
Warrants exercised
|
2020-12-31 |
| 2020-12-18 | 2670.70 | 未披露 |
更多>>
1.Common Stock offered by the company: 2,370,786 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 24,336,263 shares of common stock outstanding as of December 15, 2020.
|
2020-12-18 |
| 2020-12-18 | 2433.63 | 0.02 | 定期报告 | 2020-12-15 |
| 2020-11-12 | 2306.09 | 未披露 | 定期报告 | 2020-11-05 |
| 2020-11-12 | 2252.99 | 0.07 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock for conversion of preferred stock
Shares and (exercised) warrants issued pursuant to Securities Purchase Agreements
|
2020-09-30 |
| 2020-08-04 | 2102.88 | 未披露 |
更多>>
1.Common Stock offered by the company 1,717,106 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 19,311,731 shares of common stock outstanding as of July 31, 2020.
|
2020-08-04 |
| 2020-08-04 | 1931.17 | 0.18 | 定期报告 | 2020-07-31 |
| 2020-07-10 | 1682.98 | 未披露 |
更多>>
1.Common Stock offered by the company 1,140,570 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 15,689,223 shares of common stock outstanding as of July 9, 2020.
|
2020-07-10 |
| 2020-07-09 | 1568.92 | 0.31 | 定期报告 | 2020-07-09 |
| 2020-08-14 | 1358.83 | 0.46 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock for conversion of preferred stock
Issuance of Series Alpha preferred shares upon closing of private placement
Issuance of Series Alpha preferred stock for conversion of notes payable
Issuance of common stock for conversion of notes payable and accrued interest
Effect of reverse recapitalization
Shares and warrants issued to advisor upon closing of private placement
Stock issued for professional services
|
2020-06-30 |
| 2020-05-26 | 184.61 | 未披露 |
更多>>
1-for-25 reverse split
|
2020-05-26 |
| 2020-05-01 | 4615.30 | 未披露 | 定期报告 | 2020-04-27 |
| 2020-04-24 | 4615.30 | 未披露 | 定期报告 | 2020-04-10 |
| 2020-05-01 | 4571.39 | 0.02 |
更多>>
From December 31, 2019 to March 31, 2020
Conversion of Series B preferred shares into common stock
Issuance of common shares from ATM Agreement
Issuance of common shares from exercises of warrants
Proceeds from issuance of shares for Aspire equity line
Issuance of shares for settlement of accounts payable
|
2020-03-31 |
| 2020-03-27 | 4571.39 | 未披露 | 定期报告 | 2020-03-26 |
| 2020-03-31 | 4571.39 | 未披露 | 定期报告 | 2020-03-25 |
| 2020-03-13 | 3922.27 | 0.02 | 定期报告 | 2020-03-05 |
| 2020-02-04 | 3266.50 | 未披露 | 定期报告 | 2020-01-28 |
| 2020-03-31 | 1910.83 | 0.21 |
更多>>
From December 31, 2018 to December 31, 2019
Conversion of Series A preferred shares into common stock
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
Settlement of RSUs
Issuance of common shares from ATM Agreement
Shareholders fractional adjustment
|
2019-12-31 |
| 2019-11-14 | 1016.48 | 未披露 | 定期报告 | 2019-11-07 |
| 2019-11-14 | 992.70 | 0.62 |
更多>>
From June 30, 2019 to September 30, 2019
Conversion of Series B preferred shares into common stock
|
2019-09-30 |
| 2019-08-14 | 942.70 | 未披露 | 定期报告 | 2019-08-07 |
| 2019-07-24 | 935.00 | 未披露 | 定期报告 | 2019-07-23 |
| 2019-08-14 | 904.23 | 0.73 |
更多>>
From December 31, 2018 to June 30, 2019
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
|
2019-06-30 |
| 2019-05-15 | 904.23 | 未披露 | 定期报告 | 2019-05-10 |
| 2019-05-15 | 904.23 | 0.73 |
更多>>
from December 31, 2018 to March 31, 2019
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
|
2019-03-31 |
| 2019-04-01 | 904.23 | 未披露 | 定期报告 | 2019-03-10 |
| 2019-04-01 | 603.66 | 1.16 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of Series B preferred shares upon closing of private placement
Deemed dividend of preferred stock
Conversion of Series A preferred shares into common stock
Conversion of Series B preferred shares into common stock
|
2018-12-31 |
| 2018-11-09 | 573.46 | 0.60 | 定期报告 | 2018-09-30 |
| 2018-08-14 | 553.46 | 未披露 | 定期报告 | 2018-08-10 |
| 2018-08-14 | 533.46 | 0.76 | 定期报告 | 2018-06-30 |
| 2018-05-15 | 501.96 | 未披露 | 定期报告 | 2018-05-11 |
| 2018-05-15 | 501.96 | 未披露 | 定期报告 | 2018-05-07 |
| 2018-05-15 | 502.07 | 0.88 | 定期报告 | 2018-03-31 |
| 2018-03-22 | 494.07 | 未披露 |
更多>>
Ritter Pharmaceuticals, Inc. today announced a 1-for-10 reverse split of its Common Stock, effective March 23, 2018.As a result of the reverse stock split, the number of issued and outstanding shares of Common Stock will be reduced from approximately 49,406,521 to approximately 4,940,652.
|
2018-03-23 |
| 2018-03-19 | 4940.65 | 0.91 |
更多>>
from December 31, 2016 to December 31, 2017
Conversion of series A preferred shares
Issuance of shares upon follow-on offering
Issuance of shares under common stock purchase agreement
|
2017-12-31 |
| 2017-10-31 | 4950.65 | 未披露 | 定期报告 | 2017-10-27 |
| 2017-08-07 | 1475.65 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 1461.92 | 未披露 | 定期报告 | 2017-05-05 |
| 2017-02-27 | 1161.92 | 未披露 |
更多>>
From December 31, 2015 to December 09, 2016
Issuance of common stock upon closing of follow-on public offering
Issuance of common stock under common stock purchase agreement
Exercise of options on common stock
|
2016-12-09 |
| 2016-11-07 | 1073.04 | 未披露 |
更多>>
On October 31, 2016, the Company closed a public offering, selling 2,127,660 shares of the Company’s common stock at a price to the public of $2.35 per share, for aggregate gross proceeds to the Company of approximately $5.0 million. The Company paid to the underwriters underwriting discounts and commissions of approximately $0.4 million in connection with the offering, and approximately $0.2 million of other expenses in connection with the offering.
|
2016-11-01 |
| 2016-11-07 | 859.29 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-05-09 | 858.47 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-21 | 858.47 | 未披露 | 定期报告 | 2016-03-16 |
| 2016-03-21 | 858.20 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Conversion of all outstanding preferred stock subject to redemption to common stock
Conversion of all outstanding preferred stock to common stock
Issuance of common stock upon closing of initial public offering
Issuance of common stock upon closing of common stock purchase agreement
Issuance of common stock for commitment fee
Issuance of common stock to supplier
Exercise of options on common stock
The 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015
|
2015-12-31 |
| 2015-12-31 | 858.20 | 未披露 | 定期报告 | 2015-12-30 |
| 2015-08-12 | 779.24 | 未披露 | 定期报告 | 2015-08-04 |
| 2015-06-26 | 778.81 | 未披露 |
更多>>
1.reflects the 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015;
2.reflects the conversion of all outstanding shares of preferred stock into an aggregate of 3,322,676 shares of our common stock upon completion of this offering;
|
2015-06-24 |
| 2015-05-22 | 46.54 | 2375.72 | 定期报告 | 2015-03-31 |
| 2015-03-23 | 46.54 | 2228.72 |
更多>>
From December 31, 2013 to December 31, 2014
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock
Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767
Cumulative dividends on Series B preferred stock
Accretion of discount on Series C preferred stock
|
2014-12-31 |
From December 31, 2022 to December 31, 2023
Redemptions of convertible debt into common stock
Voluntary conversion of convertible debt into common stock
From December 31, 2022 to March 31, 2023
Voluntary conversion of convertible debt into common stock
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split.
From June 30, 2022 to September 30, 2022
Stock issued upon exercise of warrants
From December 31, 2020 to December 31, 2021
Issuance of common stock for conversion of preferred stock
Stock issued upon cash-exercise of warrants
Stock issued upon net-exercise of warrants
Shares issued pursuant to Securities Purchase Agreements
Stock issued for professional services
From June 30, 2021 to September 30, 2021
Stock issued upon cash-exercise of warrants
From March 31, 2021 to June 30, 2021
Stock issued upon cash-exercise of warrants
From December 31, 2020 To March 31, 2021
Stock issued upon cash-exercise of warrants
Stock issued upon net-exercise of warrants
Stock issued for professional services
From March 31, 2020 to December 31, 2020
Issuance of common stock for conversion of preferred stock
Issuance of common stock for conversion of notes payable and accrued interest
Effect of reverse recapitalization
Shares and warrants issued to advisor upon closing of private placement
Shares and warrants issued pursuant to Securities Purchase Agreements
Stock issued for professional services
Warrants exercised
1.Common Stock offered by the company: 2,370,786 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 24,336,263 shares of common stock outstanding as of December 15, 2020.
From June 30, 2020 to September 30, 2020
Issuance of common stock for conversion of preferred stock
Shares and (exercised) warrants issued pursuant to Securities Purchase Agreements
1.Common Stock offered by the company 1,717,106 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 19,311,731 shares of common stock outstanding as of July 31, 2020.
1.Common Stock offered by the company 1,140,570 shares of common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 15,689,223 shares of common stock outstanding as of July 9, 2020.
From March 31, 2020 to June 30, 2020
Issuance of common stock for conversion of preferred stock
Issuance of Series Alpha preferred shares upon closing of private placement
Issuance of Series Alpha preferred stock for conversion of notes payable
Issuance of common stock for conversion of notes payable and accrued interest
Effect of reverse recapitalization
Shares and warrants issued to advisor upon closing of private placement
Stock issued for professional services
1-for-25 reverse split
From December 31, 2019 to March 31, 2020
Conversion of Series B preferred shares into common stock
Issuance of common shares from ATM Agreement
Issuance of common shares from exercises of warrants
Proceeds from issuance of shares for Aspire equity line
Issuance of shares for settlement of accounts payable
From December 31, 2018 to December 31, 2019
Conversion of Series A preferred shares into common stock
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
Settlement of RSUs
Issuance of common shares from ATM Agreement
Shareholders fractional adjustment
From June 30, 2019 to September 30, 2019
Conversion of Series B preferred shares into common stock
From December 31, 2018 to June 30, 2019
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
from December 31, 2018 to March 31, 2019
Conversion of Series B preferred shares into common stock
Conversion of Series C preferred shares into common stock
from December 31, 2017 to December 31, 2018
Issuance of Series B preferred shares upon closing of private placement
Deemed dividend of preferred stock
Conversion of Series A preferred shares into common stock
Conversion of Series B preferred shares into common stock
Ritter Pharmaceuticals, Inc. today announced a 1-for-10 reverse split of its Common Stock, effective March 23, 2018.As a result of the reverse stock split, the number of issued and outstanding shares of Common Stock will be reduced from approximately 49,406,521 to approximately 4,940,652.
from December 31, 2016 to December 31, 2017
Conversion of series A preferred shares
Issuance of shares upon follow-on offering
Issuance of shares under common stock purchase agreement
From December 31, 2015 to December 09, 2016
Issuance of common stock upon closing of follow-on public offering
Issuance of common stock under common stock purchase agreement
Exercise of options on common stock
On October 31, 2016, the Company closed a public offering, selling 2,127,660 shares of the Company’s common stock at a price to the public of $2.35 per share, for aggregate gross proceeds to the Company of approximately $5.0 million. The Company paid to the underwriters underwriting discounts and commissions of approximately $0.4 million in connection with the offering, and approximately $0.2 million of other expenses in connection with the offering.
from December 31, 2014 to December 31, 2015
Conversion of all outstanding preferred stock subject to redemption to common stock
Conversion of all outstanding preferred stock to common stock
Issuance of common stock upon closing of initial public offering
Issuance of common stock upon closing of common stock purchase agreement
Issuance of common stock for commitment fee
Issuance of common stock to supplier
Exercise of options on common stock
The 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015
1.reflects the 1-for-7.15 reverse stock split of our common stock effected on June 17, 2015;
2.reflects the conversion of all outstanding shares of preferred stock into an aggregate of 3,322,676 shares of our common stock upon completion of this offering;
From December 31, 2013 to December 31, 2014
Conversion of notes payable into preferred stock subject to redemption and warrants to purchase common stock
Issuance of preferred stock subject to redemption and warrants to purchase common stock, net of offering cost of $68,767
Cumulative dividends on Series B preferred stock
Accretion of discount on Series C preferred stock